Dr Liao and co-workers from Taiwan aimed to evaluate whether adding GLP-1 RA to SGLT2i provides additional benefits in patients with both atherosclerotic cardiovascular disease (ASCVD) and heart failure (HF). The gene discussed is GLP1R; the disease is atherosclerosis.